The Lived Experience of Medication for Opioid Use Disorder: Qualitative Metasynthesis.
Aimee Techau, Emily Gamm, Mia Roberts and 1 others
PMID 37669351WHAT IT FOUND
Patients on medication for opioid use disorder described it as both a savior and an oppressor.
They valued reduced cravings and dignity but feared surveillance, stigma, and side effects like dulled emotions. Treatment structure and personal identity heavily shaped whether the experience felt supportive or controlling.
Key findings
01Stigmatization was present in all nine included studies, with participants facing judgment from providers, family, and the public who viewed medication as substituting one drug for another.
02Participants reported ambivalence: medication managed cravings and improved sleep, but also caused intolerable side effects like dulled emotions and difficult withdrawal.
03Buprenorphine was perceived as less stigmatizing and more flexible because it is prescribed in primary care, whereas methadone was associated with greater surveillance and obligation in treatment programs.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The synthesis included only nine studies, which limits the breadth of evidence. The quality of the primary studies varied, with few reporting audit trails or data saturation. The studies were conducted in different countries and treatment settings (e.g., prisons, outpatient clinics), which may affect how findings apply to specific local contexts. Most studies did not consistently report the specific breakdown of participants on methadone versus buprenorphine.
Declared interests
The authors declare no conflicts of interest. One author is a psychiatric and addictions nurse practitioner who conducted the literature search.
The easy way to misread this
Do not interpret these themes as evidence that medication causes addiction or worsens outcomes. The study reports patients' subjective experiences of stigma and side effects, not a failure of the medication's efficacy in reducing overdose or retaining patients in care.